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Abstract
Background: Colorectal cancer is the third most common cancer and the third leading cause of cancer-related
death. Bevacizumab is a humanized monoclonal antibody developed against vascular endothelial growth factor
(VEGF) for the treatment of metastatic cancer. The parameters of RECIST (Response Evaluation Criteria for Solid
Tumors) are not adequate to detect important treatment effects and response. Our goal was to evaluate the
possibility of using sTRAIL (serum-soluble TNF-related apoptosis-inducing ligand) and VEGF as markers of treatment
efficacy and prognosis in patients with metastatic colon cancer.
Methods: sTRAIL and VEGF levels were measured by ELISA in the sera of 16 bevacizumab-treated metastatic colon
cancer patients and 10 presumably healthy age-matched controls. The measurements were taken before and after
treatment for comparison purposes.
Results: Elevated levels of sTRAIL were found in seven out of 16 patients after bevacizumab treatment. Although
these patients had a median survival time of 20.6 months, the remaining bevacizumab-treated patients who did
not show an increase in sTRAIL had a median survival time of 9.4 months. As expected, serum VEGF levels were
decreased in all patients who received bevacizumab therapy and showed no correlation between serum VEGF
levels and patient survival (data not shown).
Conclusions: Serum sTRAIL levels might be a useful predictor of prognosis in metastatic colon cancer, in the early
evaluation stages following bevacizumab treatment.
Background
Colorectal cancer is the third most common cancer and
the second leading cause of cancer-related death [1].
Overall, the 5-year survival rate is <10% for stage IV
cancer [2]. The cure rate with surgery alone is very low
and chemotherapy and radiotherapy are usually needed
in patients with untreated metastatic colon cancer. The
development of colorectal cancer is characterized by a
sequence of events during which normal colonic epithe-
lium gradually transforms to carcinoma tissue, in most
cases, via the development of colorectal adenomas [3].
This sequence of events is driven by an accumulation of
molecular (epi)genetic alterations causing progressive
disorders in cell growth, differentiation and apoptosis
[4,5]. Apoptosis, or programmed cell death, plays an
important role in the development and maintenance of
tissue homeostasis but also represents an effective
mechanism by which abnormal cells, such as tumor
cells, can be eliminated [6-8]. Abnormalities in apoptotic
function or resistance to apoptosis have been identified
as important events in the pathogenesis of colorectal
cancer and its resistance to chemotherapeutic drugs and
radiotherapy [9,10].
In recent years, bevacizumab, a novel humanized
monoclonal antibody directed against vascular endothe-
lial growth factor (VEGF) has found widespread clinical
use as an angiogenesis inhibitor for certain types of
metastatic cancers [11]. Treatment with bevacizumab
with/without the combination of other chemotherapeu-
tic agents inhibits VEGF receptor activation and vascular
permeability, which eventually lead to tumor cell apop-
tosis [12,13]. Apoptosis can be induced passively,
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any medium, provided the original work is properly cited.through the lack of essential survival signals, or actively,
through the ligand-induced trimerization of specific
death receptors of the tumor necrosis factor (TNF)
receptor family, such as Fas, the TNF receptor, or
TRAIL (TNF-related apoptosis-inducing ligand) receptor
[14].
TRAIL (APO-2 ligand) is a transmembrane (type II)
glycoprotein that also belongs to the TNF superfamily.
The extracellular domain of TRAIL is homologous to
that of other family members and shows a homotrimeric
s u b u n i ts t r u c t u r e .L i k eT N Fa n dF a sl i g a n d( F A S L ) ,
TRAIL also exists physiologically in a biologically active
soluble homotrimeric form, serum-soluble TRAIL;
sTRAIL [15]. Several recent studies have indicated that
sTRAIL is involved in the pathophysiology of different
disease states such as cancer, viral infections, autoim-
mune diseases and inflammation, and defective apopto-
sis due to its interaction with its ligand preventing
signaling for apoptosis may contribute to these diseases
[16-21].
Several studies have shown that both the membrane-
bound TRAIL and sTRAIL can induce apoptosis in a
wide variety of tumor types by activating death receptors
[22-24]. sTRAIL is also used as a positive marker for
apoptosis [25]. However, it has been observed that the
cytotoxic effects of antiangiogenic agents are increased
in clinical phase II and III studies when these agents are
combined with TRAIL-related therapies [26-28].
Another study with human glioblastoma cells has indi-
cated that TRAIL inhibits angiogenesis stimulated by
VEGF expression [29].
However, recently used RECIST parameters (Response
Evaluation Criteria for Solid Tumors; responders vs.
non-responders) are not adequate to document the dif-
ferences in treatment response [30]. Therefore, there is
a need for a sensitive, specific and reliable serum marker
to monitor the therapeutic response.
The purpose of our study was to evaluate the possible
use of sTRAIL as a marker for bevacizumab treatment
efficacy at the cell apoptosis-linked step.
Methods
The amount of released sTRAIL and VEGF was mea-
sured by ELISA in the serum of 16 metastatic colon
cancer patients with liver metastases, who also received
bevacizumab therapy, and 10 age- and sex-matched
healthy control individuals who did not receive the
treatment. Serum samples were obtained before bevaci-
zumab-based chemotherapyr e g i m e n sa n d3m o n t h s
after. Serum samples were kept between 2 and 8°C, cen-
trifuged at 10,000 rpm for 10 min, and then frozen at
-81°C until assayed.
ELISA was done using the Diaclone sTRAIL ELISA kit
(Gen-Probe, Besancon, France) according to the
manufacturer’s instructions. Statistical analyses were
performed using SPSS for Windows version 13.0 (SPSS
Inc., Chicago, IL, USA). Group comparisons were made
using the independent samples t test. Progression-free
survival (PFS) was defined as the period from the begin-
ning of chemotherapy until documented progression or
death from any cause. Overall survival (OS) was defined
as the period from the first day of treatment until the
date of last follow-up or death.
Written informed consent relating to the Declaration
of Helsinki was obtained from all patients. The study
was approved by Akdeniz University Local Committee
on Ethics.
Results
The baseline clinical characteristics of the patients are
summarized in Table 1. The serum sTRAIL concentra-
tions before therapy were similar to those of the con-
trols (Figure 1). Serum sTRAIL levels in metastatic
colorectal cancer (MCRC) patients before bevacizumab-
based chemotherapy and healthy controls were 1.12 ±
0.04 ng/ml and 1.17 ± 0.08 ng/ml, respectively. After
bevacizumab treatment, seven out of 16 patients’ post-
treatment sTRAIL ratios were significantly increased as
shown in Figure 2.
Nine patients had progressive diseases, resulting in an
overall response rate (56.2%). Median overall survival
was 9.4 ± 0.9 months in non-responders. Interestingly,
these nine patients were the same ones who showed no
increase in sTRAIL levels after bevacizumab treatment.
Therefore, we wanted to know whether there was any
correlation between sTRAIL levels and overall survival
rates. Our study demonstrated that elevated sTRAIL
levels after bevacizumab treatment were significantly
associated with increased median overall survival of up
to 20.6 months (Table 2).
Not surprisingly, the serum VEGF levels were
decreased in all patients who received bevacizumab
therapy (data not shown). Serum VEGF levels in MCRC
patients before bevacizumab-based chemotherapy were
211 ± 189 ng/ml, and 3 months after treatment, they
decreased to 117 ± 18.9 ng/ml, similar to healthy con-
trols (119.5 ± 35.1 ng/ml).





Age 51, 8 55, 18
Sex Male 8 (%80) 12(%75)
Female 2(%20) 4(%25)
Age and sex distribution of metastatic colon cancer patients (n = 16) and
healthy control individuals (n = 10)
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MCRC is mainly treated with combination of bevacizu-
mab and irinotecan or oxaliplatin-based chemotherapy.
The role of TRAIL and another apoptotic marker FAS/
FASL systems in CRC patients treated with chemothera-
peutic agents has been discussed previously [31-33]. The
use of sTRAIL is a novel concept for which few data
exist. We evaluated sTRAIL ratio as a marker of che-
motherapeutic responsiveness in MCRC patients. This is
believed to be the first study in which changes in levels
of sTRAIL after bevacizumab treatment have been esti-
mated in overall survival of MCRC patients.
In this study, we compare the levels of sTRAIL in
responders versus non-responders to bevacizumab ther-
apy. In responding patients, sTRAIL level increased, but
the level decreased or was unchanged in non-respon-
ders. This significant change may be a result of the
effect of bevacizumab on cancer cells via apoptosis.
Another study has found that, although there was no
significant difference between sTRAIL, soluble death
receptor (sDR)4 and sDR5 levels in MCRC patients
before and after treatment, significant correlations were
observed between post-treatment sFASL and sDR4,
post-treatment sFAS and sTRAIL, post-treatment
sTRAIL and sFAS/sFASL ratio, and post-treatment
sFASL and sDR5 [34]. This controversy may also have
been due to the patients enrolled in the study. Although
we chose newly diagnosed patients who had bevacizu-
mab as first-line treatment, in the other study, patients
were mostly treated with bevacizumab-based che-
motherapy in the second-line setting after failure of oxa-
liplatin-based chemotherapy.
There have been many studies that have focused on
identifying biomarkers for prediction of bevacizumab
efficacy. The most obvious protein biomarker to select
for testing bevacizumab efficacy is VEGF, but no studies
have yet found changes in VEGF concentrations during
therapy to have consistent predictive value [35]. One
study has found that circulating levels of intercellular
adhesion molecule (ICAM)-1 to be at least potentially
predictive of survival benefit. Other studies have sug-
gested that neutropenia might have a negative effect on
bevacizumab efficacy. There have also been other stu-
dies that have concluded that polymorphisms in the
VEGF pathway may have predictive value [36,37]. How-
ever, although several candidate biomarkers have already
been described, including tumor and plasma VEGF, cir-
culating E-selectin, ICAM-1 and vascular cell adhesion
molecule-1, much more work is needed to determine
the most effective biomarkers and thus to select the
patients that are most likely to benefit from bevacizu-
mab therapy [36].
As a conclusion, our study gave a different perspec-
tive on MCRC and bevacizumab treatment efficacy in
relation to apoptosis and serum sTRAIL levels. The
Figure 1 Serum sTRAIL levels. No difference between two groups
(P = 0.50) before bevacizumab treatment: 1.12 ± 0.04 ng/ml in
metastatic colon cancer patients and 1.17 ± 0.08 ng/ml in healthy
control individuals.
Figure 2 Serum sTRAIL levels after treatment. Elevated levels of
sTRAIL were found in seven out of 16 metastatic colon cancer
patients whose serum sTRAIL concentrations were similar to those
of healthy age- and sex-matched control individuals (n = 10) before
bevacizumab therapy, as seen in Figure 1. These increases were
significant compared with pretreatment measurements (P < 0.001).
The increase or decrease in the serum levels were shown as
percentage change in serum sTRAIL.




Serum sTRAIL Level (ng/
ml)
Alive (n = 7) 20,6 ± 0,5 1,38 ± 0,10




p < 0,05 (p =
0,0001)
p < 0,05 (p = 0,0002)
Metastatic colon cancer patients who were treated with bevacizumab, and
had increased levels of serum sTRAIL after treatment, had an extended
median survival time up to 20.6 months. In contrast, median survival was 9.4
months for patients with decreased or unchanged sTRAIL after the
bevacizumab therapy
Bisgin et al. BMC Cancer 2012, 12:58
http://www.biomedcentral.com/1471-2407/12/58
Page 3 of 5present data highlight the potential importance of
sTRAIL in this setting. Further study with a larger
patient population and longer duration is warranted to
clarify its value.
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